Literature DB >> 29277757

In Vitro Evaluation of Humanized/De-immunized Anti-PSMA Immunotoxins for the Treatment of Prostate Cancer.

Marta Michalska1, Susanne Schultze-Seemann1, Irina Kuckuck1, Philipp Wolf2.   

Abstract

BACKGROUND: We generated humanized/de-immunized immunotoxins targeting the prostate-specific membrane antigen (PSMA) and tested their cytotoxic activity against prostate cancer cells in vitro.
MATERIALS AND METHODS: The humanized/de-immunized version of our murine anti-PSMA single-chain antibody fragment (scFv) D7, termed hD7-1(VL-VH), was ligated to the 40-kDa toxin domain of Pseudomonas aeruginosa exotoxin A (PE40), and to the deimmunized 24-kDa toxin domains PE24 or PE24mut. The immunotoxins designated as hD7-1(VL-VH)-PE40, hD7-1(VL-VH)-PE24 and hD7-1(VL-VH)-PE24mut were bacterially expressed and purified by affinity chromatography. Binding and cytotoxicity were examined by flow cytometry and viability assay, respectively.
RESULTS: All immunotoxins revealed strong binding to prostate cancer cells expressing PSMA and specific cytotoxicity, with half-maximal inhibitory concentration values in the picomolar range.
CONCLUSION: We successfully created powerful anti-PSMA immunotoxins with reduced immunogenicity for further clinical development and application against advanced prostate cancer. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Immunotoxin; PSMA; Pseudomonas exotoxin A; deimmunization; prostate cancer

Mesh:

Substances:

Year:  2018        PMID: 29277757     DOI: 10.21873/anticanres.12192

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.435


  4 in total

1.  PSMA-Directed CAR T Cells Combined with Low-Dose Docetaxel Treatment Induce Tumor Regression in a Prostate Cancer Xenograft Model.

Authors:  Jamal Alzubi; Viviane Dettmer-Monaco; Johannes Kuehle; Niko Thorausch; Maximilian Seidl; Sanaz Taromi; Wolfgang Schamel; Robert Zeiser; Hinrich Abken; Toni Cathomen; Philipp Wolf
Journal:  Mol Ther Oncolytics       Date:  2020-06-24       Impact factor: 7.200

2.  Therapeutic effects of human monoclonal PSMA antibody-mediated TRIM24 siRNA delivery in PSMA-positive castration-resistant prostate cancer.

Authors:  Sheng-Jia Shi; Li-Juan Wang; Dong-Hui Han; Jie-Heng Wu; Dian Jiao; Kai-Liang Zhang; Jiang-Wei Chen; Yu Li; Fa Yang; Jing-Liang Zhang; Guo-Xu Zheng; An-Gang Yang; Ai-Zhi Zhao; Wei-Jun Qin; Wei-Hong Wen
Journal:  Theranostics       Date:  2019-02-07       Impact factor: 11.556

3.  Structural basis of prostate-specific membrane antigen recognition by the A9g RNA aptamer.

Authors:  Jakub Ptacek; Dong Zhang; Liming Qiu; Sven Kruspe; Lucia Motlova; Petr Kolenko; Zora Novakova; Shambhavi Shubham; Barbora Havlinova; Petra Baranova; Shi-Jie Chen; Xiaoqin Zou; Paloma Giangrande; Cyril Barinka
Journal:  Nucleic Acids Res       Date:  2020-11-04       Impact factor: 16.971

4.  In silico identification and modification of T cell epitopes in pertussis antigens associated with tolerance.

Authors:  Corine Kruiswijk; Guilhem Richard; Merijn L M Salverda; Pooja Hindocha; William D Martin; Anne S De Groot; Elly Van Riet
Journal:  Hum Vaccin Immunother       Date:  2020-01-17       Impact factor: 3.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.